Plavix vs. Brilinta
Plavix vs. Brilinta
Eli Lilly said Tuesday it is halting the development of an Alzheimer's treatment after studies showed the experimental drug semagacestat not only failed to slow the disease's progression, it actually reduced patients' cognition.
Several biotech stocks were on the move Monday after Deutsche Bank initiated coverage on some of them. The bank's analyst, Robyn Karnauskas, took a generally wary view on the biotech sector, only putting buy ratings on Gilead and Dendreon.
In a case that tested the bounds of the First Amendment, Hal Turner, a right-wing radio shock jock, was convicted of threatening three judges' lives in his blog post. Plus, Eli Lilly loses a patent case for ADHD drug Strattera.
Foreign subsidiaries of two American tobacco companies pled guilty to charges of bribing foreign countries. Units of Alliance One Int'l, a N.C.-based global tobacco leaf company, admitted bribing Thai and Kyrgyz officials and will pay $9.25 million in fines and disgorge $10 million in profits.
Eli Lilly Earnings Top Estimates
The U.S. Food and Drug Administration rejected Boehringer Ingelheim's pink pill, flibanserin, which aims to boost women's sex drive.
Pharmaceutical giant Roche said Friday that it would delay an FDA filing for its new diabetes drug for 12 to 18 months due to safety concerns. The beneficiary of Roche's misfortune is rival Amylin, which now jumps ahead in the race to get first approval of a once-weekly injectable type 2 diabetes drug.
A new database of Alzheimer's patients from failed trials built by a dozen competing drug companies may offer some hope for Alzheimer's research and treatment breakthroughs.
The following is a round-up of news likely to affect stock prices today:
Goldman Sachs Group Inc. (GS) sank nearly 13% on Friday after the...
The markets continued to rack up gains with the Dow Jones Industrial Average, S&P 500 and NASDAQ all closing Wednesday at 18-month highs, boosted by signs that the Federal Reserve intends to keep interest rates at rock-bottom levels for some time, indicating that the Fed isn't worried about inflation.
Thieves broke into a Connecticut Eli Lilly warehouse over the weekend and stole about $75 million in prescription drugs.
The FDA has nearly doubled the warning letters it's sent to drugmakers for questionable promotion in the past year. But some critics say the fines don't go far enough, and that Big Pharma merely views the penalties as the price of doing business.
First it was restructurings to adjust to fewer patented blockbusters. Then it was the recession. Now it's just more of the same as SmithKlineGlaxo and AstraZeneca add to the unemployment rolls. In the West, that is. Hiring is strong in emerging markets.
Eli Lilly & Co. (LLY), the pharmaceutical company behind antidepressant medication Prozac and erectile dysfunction drug Cialis, reported strong sales in the fourth quarter, as expected.
Pharmaceutical giant Eli Lilly -- maker of Prozac and Cialis -- is expected to post solid fourth-quarter profits on Thursday after a recent restructuring. But the results will likely be lower than the year-ago quarter.
Federal regulators approved Novo Nordisk's new once-daily injection for treating Type 2 diabetes Victoza, driving shares higher. Shares of Amylin Pharmaceuticals also rallied as the approval of Victoza raises hopes that Amylin's rival drug will also get the greenlight.
President Obama can't be pleased by the loss of a Democratic Senate seat which jeopardizes passage of his cherished health-care reform. The news, however, appears to have fueled a mini stock rally in the health-care and pharma sectors wary of how any reform would affect their businesses. The uptrend is expected to continue.
Hollywood has long made light of premature ejaculation. Jason Biggs's scene in the teen movie American Pie is pretty typical: guy finally gets girl...
The U.S. diabetes drug market just got a little more competitive. Swiss drugmaker Roche (RHHBY) said Wednesday an experimental medicine in late-stage development works better in treating type 2 diabetes than Merck (MRK) Januvia, according to a clinical study.
It seems that when it comes to Aranesp, its blockbuster anemia drug, Amgen (AMGN) just can't catch a break, nor for that matter, create one....
A popular eyelash-enhancing drug's promotional materials are raising eyebrows among federal regulators. The U.S. Food and Drug Administration has...